Inmune Bio, Inc. financial data

Symbol
INMB on Nasdaq
Location
225 Ne Mizner Blvd, Suite 640, Boca Raton, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Oct 30, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 355 % +62.9%
Debt-to-equity 27.9 % -40.7%
Return On Equity -46.3 %
Return On Assets -134 % -70.3%
Operating Margin -26.2K % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.6M shares +19.9%
Common Stock, Shares, Outstanding 26.6M shares +19.9%
Entity Public Float 135M USD +27.4%
Common Stock, Value, Issued 27K USD +22.7%
Weighted Average Number of Shares Outstanding, Basic 26.6M shares +31.7%
Weighted Average Number of Shares Outstanding, Diluted 26.6M shares +31.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 50K USD +257%
Research and Development Expense 25.7M USD -19.3%
General and Administrative Expense 9.23M USD -5.53%
Operating Income (Loss) -51.4M USD -23.7%
Nonoperating Income (Expense) 961K USD +398%
Net Income (Loss) Attributable to Parent -49.9M USD -20.9%
Earnings Per Share, Basic -2 USD/shares +2.75%
Earnings Per Share, Diluted -2 USD/shares +2.75%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 27.7M USD -17.3%
Accounts Receivable, after Allowance for Credit Loss, Current 1.7M USD +53.7%
Assets, Current 30.7M USD -14.5%
Property, Plant and Equipment, Net 878K USD
Operating Lease, Right-of-Use Asset 1.06M USD +218%
Intangible Assets, Net (Excluding Goodwill) 16.5M USD 0%
Other Assets, Noncurrent 746K USD +810%
Assets 33.4M USD -36.8%
Liabilities, Current 7.36M USD -46.8%
Operating Lease, Liability, Noncurrent 623K USD +119%
Liabilities 7.98M USD -43.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -764K USD +26.3%
Retained Earnings (Accumulated Deficit) -204M USD -32.4%
Stockholders' Equity Attributable to Parent 25.4M USD -34.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 50.7M USD -27.6%
Liabilities and Equity 33.4M USD -36.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.82M USD +8.72%
Net Cash Provided by (Used in) Financing Activities 5.27M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 26.6M shares +19.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.59M USD +83.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 27.7M USD -17.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 302K USD -32.9%
Deferred Tax Assets, Valuation Allowance 25.7M USD +31%
Deferred Tax Assets, Gross 25.7M USD +31.1%
Operating Lease, Liability 1.08M USD +158%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -49.6M USD -19.3%
Lessee, Operating Lease, Liability, to be Paid 1.2M USD
Operating Lease, Liability, Current 457K USD +239%
Lessee, Operating Lease, Liability, to be Paid, Year Two 405K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 729K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 122K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 51K USD -74.2%
Deferred Tax Assets, Operating Loss Carryforwards 8.69M USD +26.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 51K USD
Operating Lease, Payments 152K USD
Additional Paid in Capital 230M USD +18.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 545K USD
Share-based Payment Arrangement, Expense 2.98M USD +73.6%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%